Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist Watchlist | Portfolio Portfolio | Dashboard Dashboard
Hi,
Site News
Contact
Market:
Your Free 7-Day Premier trial ends on . Extend Your Trial For Another 30 Days. Time remaining
Faster, Cleaner, Better.

Affimed N.V. (AFMD)

Affimed N.V. (AFMD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Help
Go To:
Affimed Announces Receipt of Nasdaq Delisting Notice GlobeNewswire - Wed May 14, 2025

MANNHEIM, Germany, May 14, 2025 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients...

AFMD : 0.1815 (-34.95%)
Affimed Announces Filing for the Opening of Insolvency Proceedings GlobeNewswire - Tue May 13, 2025

MANNHEIM, Germany, May 13, 2025 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients...

AFMD : 0.1815 (-34.95%)
Affimed Shows Higher Exposure of AFM24 is Associated with Significantly Higher Response Rates and Progression-Free Survival in Refractory NSCLC Patients at AACR Annual Meeting GlobeNewswire - Tue Apr 29, 2025

An exposure-outcome analysis in 72 patients with refractory non-small cell lung cancer (NSCLC) who received AFM24 at 480 mg weekly demonstrates that higher...

AFMD : 0.1815 (-34.95%)
Affimed Announces Acceptance of Three Abstracts for Presentation at the American Society for Clinical Oncology Annual Meeting GlobeNewswire - Wed Apr 23, 2025

MANNHEIM, Germany, April 23, 2025 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company...

AFMD : 0.1815 (-34.95%)
Affimed Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price Requirement GlobeNewswire - Mon Apr 21, 2025

MANNHEIM, Germany, April 21, 2025 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients...

AFMD : 0.1815 (-34.95%)
Affimed Announces Acceptance of AFM24 Abstract on Dose Optimization for Presentation at American Association for Cancer Research Annual Meeting GlobeNewswire - Tue Mar 25, 2025

MANNHEIM, Germany, March 25, 2025 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients...

AFMD : 0.1815 (-34.95%)
Affimed N.V. Reports Promising 40% Complete Remission Rate for AFM28 in Heavily Pretreated R/R AML Patients Quiver Quantitative, Inc. - Mon Dec 9, 2024

AFM28 shows 40% complete remission rate in R/R AML patients with manageable safety profile in Phase 1 trial.Quiver AI SummaryAffimed N.V. announced promising results for its bispecific innate cell engager,...

AFMD : 0.1815 (-34.95%)
Affimed N.V. Reports Encouraging Efficacy of Acimtamig Combined with AlloNK® in R/R Classical Hodgkin Lymphoma at ASH Annual Meeting Quiver Quantitative, Inc. - Sun Dec 8, 2024

Acimtamig with AlloNK® shows 86% response rate in relapsed/refractory classical Hodgkin lymphoma, with manageable safety.Quiver AI SummaryAffimed N.V. announced promising results from a study combining...

AFMD : 0.1815 (-34.95%)
AFMD Stock Down Despite FDA's RMAT Status for Lymphoma Therapy
AFMD Stock Down Despite FDA's RMAT Status for Lymphoma Therapy Zacks Investment Research - Fri Dec 6, 2024

Affimed N.V. AFMD announced that the FDA has granted the Regenerative Medicine Advanced Therapy (RMAT) designation to its pipeline candidate, acimtamig (AFM13).The regulatory body granted the RMAT designation...

AFMD : 0.1815 (-34.95%)
CSTL : 33.57 (+1.63%)
SPRO : 1.2050 (-1.23%)
ARTV : 11.24 (-0.53%)
Affimed Receives FDA RMAT Designation for Acimtamig and Artiva’s AlloNK® in Relapsed/Refractory Hodgkin Lymphoma Treatment Quiver Quantitative, Inc. - Thu Dec 5, 2024

Affimed's acimtamig and Artiva's AlloNK® receive FDA RMAT designation for treating relapsed/refractory Hodgkin Lymphoma based on promising early data.Quiver AI SummaryAffimed N.V. announced that the U.S....

AFMD : 0.1815 (-34.95%)

Barchart Exclusives

1 Cheap Stock Under $10 for Aggressive Investors to Buy on the Dip Barchart - 25 minutes ago
Miniso shares hit a multi-year low after weak Q2 2026 results exposed deteriorating overseas profitability. Despite analyst downgrades, a cheap valuation and a new buyback-focused capital return plan make it a speculative rental play, not a long-term hold. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.